{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T05:50:13Z","timestamp":1771048213991,"version":"3.50.1"},"reference-count":30,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2013,3,19]],"date-time":"2013-03-19T00:00:00Z","timestamp":1363651200000},"content-version":"vor","delay-in-days":2756,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2005,9]]},"abstract":"<jats:p>Prolongation of QT interval on an electrocardiogram is a valuable predictor of a drug's ability to cause potentially fatal ventricular tachyarrhythmia (torsades de pointes). Darifenacin is a muscarinic M<jats:sub>3<\/jats:sub> selective receptor antagonist developed for the treatment of overactive bladder, a debilitating condition that is particularly prevalent in the older population. This 7\u2010day, randomized, parallel\u2010group study (n = 188) measured QT\/QTc interval in healthy volunteers receiving once\u2010daily darifenacin at steady\u2010state therapeutic (15 mg) and supratherapeutic (75 mg) doses, alongside controls receiving placebo or moxifloxacin (positive control, 400 mg) once daily. There was no significant increase in QTcF interval with darifenacin treatment compared with placebo. Mean changes from baseline at pharmacokinetic T<jats:sub>max<\/jats:sub> versus placebo were \u22120.4 and \u22122.2 milliseconds in the darifenacin 15 mg and 75 mg groups, respectively, compared with +11.6 milliseconds in the moxifloxacin group (P &lt;.01). This study demonstrates that darifenacin does not prolong QT\/QTc interval.<\/jats:p>","DOI":"10.1177\/0091270005279010","type":"journal-article","created":{"date-parts":[[2005,8,12]],"date-time":"2005-08-12T17:08:43Z","timestamp":1123866523000},"page":"1038-1047","source":"Crossref","is-referenced-by-count":52,"title":["QT and QTc Interval With Standard and Supratherapeutic Doses of Darifenacin, a Muscarinic M<sub>3<\/sub> Selective Receptor Antagonist for the Treatment of Overactive Bladder"],"prefix":"10.1002","volume":"45","author":[{"given":"Denise B.","family":"Serra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melton B.","family":"Affrime","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin P.","family":"Bedigian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Greig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slavica","family":"Milosavljev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrej","family":"Skerjanec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yibin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,19]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(98)00585-2"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.067140"},{"key":"e_1_2_5_6_2","first-page":"21","article-title":"Darifenacin is selective for the human recombinant M3 receptor subtype [abstract]","author":"Napier CP","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2680.2001.00231.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0022-5347(18)37797-8","article-title":"A comparison of muscarinic receptor\u2010mediated function in the normal and the neurogenic overactive bladder [abstract]","volume":"171","author":"Stevens L","year":"2004","journal-title":"J Urol"},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0022-5347(18)37789-9","article-title":"Muscarinic receptor function in the idiopathic overactive bladder [abstract]","volume":"171","author":"Stevens L","year":"2004","journal-title":"J Urol"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(02)00045-3"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra032426"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.16.2120"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1108"},{"key":"e_1_2_5_14_2","first-page":"353","article-title":"An analysis of the time relationship to the electrocardiogram","volume":"7","author":"Bazett HC","year":"1920","journal-title":"Heart"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1542-474X.2003.08413.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)90035-B"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.111482"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/58.5.379"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.02.034"},{"key":"e_1_2_5_20_2","unstructured":"Enablex (darifenacin) US Prescribing Information.December 2004. Available at:http:www.pharma.us.novartis.comproductpipdfenablex.pdf."},{"key":"e_1_2_5_21_2","unstructured":"Human Cytochrome P450 (CYP) Allele Nomenclature Committee.Available at:http:www.imm.ki.seCYPallelesdefault.htm."},{"key":"e_1_2_5_22_2","first-page":"206","article-title":"Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"48","author":"World Medical Association.","year":"2002","journal-title":"J Postgrad Med"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1021\/ac9507552"},{"key":"e_1_2_5_24_2","volume-title":"ICH E14 document: the clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non\u2010arrhythmic drugs","author":"European Medicines Evaluation Agency.","year":"2002"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/004982598238859"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.125783"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)90481-4"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.302.6790.1469-c"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.74.1.53"},{"key":"e_1_2_5_30_2","unstructured":"Food and Drug Administration.The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non\u2010antiarrhythmic drugs. [preliminary concept paper]. November 15 2002. Available at:http:www.fda.gov."},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05454.x"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270005279010","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270005279010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T05:50:36Z","timestamp":1697435436000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270005279010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["10.1177\/0091270005279010"],"URL":"https:\/\/doi.org\/10.1177\/0091270005279010","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}